drugset
drugset / Trial / NCT07067905

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

NCT07067905 ↗

Phase 0 Recruiting 15 enrolled Chinese PLA General Hospital Sinotau Pharmaceutical Group · collab
NaSingle-groupOpen-labelDiagnostic

Summary

A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.

Timeline

Start
2025-06-27
Primary completion
2026-04-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-XT771 Diagnostic / imaging agent 148 mbq Intravenous
Subject 68Ga-XT771 Diagnostic / imaging agent 296 mbq Intravenous

Indications

No indication recorded.